Skip to main content

Market Overview

India Approves Its First Emergency-Use COVID-19 Vaccine

Share:
India Approves Its First Emergency-Use COVID-19 Vaccine

Some 300 million people in India are set to get the vaccine made by AstraZeneca and Oxford University.

What Happened: India, which has a population of 1.35 billion people, has approved its first COVID-19 vaccine and has three more in the works.

India has the second-highest number of infections among the world's countries, after the U.S. The Serum Institute of India is producing the AstraZeneca plc (NASDAQ: AZN) and Oxford University vaccine, called Covishield.

The country aims to inoculate 300 million in the first six to eight months of this year, according to Reuters. Vaccinations are expected to begin within a week, according to The Hindu.

Why It Matters: Vaccine rollouts are picking up pace throughout the world. Covishield has the advantage of being easier to store and transport, not requiring the very low temperatures that others do, including the one developed by Moderna Inc (NASDAQ: MRNA) and the one jointly developed by Pfizer Inc (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX). Authorities in the U.K. approved Covishield earlier in the week.

 

Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: Covid-19 India Pandemic VaccinesBiotech News General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com